| Detection of SARS-CoV-2 in a cat owned by a COVID-19− affected patient in Spain J Segalés, M Puig, J Rodon, C Avila-Nieto, J Carrillo, G Cantero, ... Proceedings of the National Academy of Sciences 117 (40), 24790-24793, 2020 | 192 | 2020 |
| Stable neutralizing antibody levels 6 months after mild and severe COVID-19 episodes E Pradenas, B Trinité, V Urrea, S Marfil, C Ávila-Nieto, ... Med 2 (3), 313-320. e4, 2021 | 105 | 2021 |
| SARS-CoV-2 infection elicits a rapid neutralizing antibody response that correlates with disease severity B Trinité, F Tarrés-Freixas, J Rodon, E Pradenas, V Urrea, S Marfil, ... Scientific Reports 11 (1), 2608, 2021 | 97 | 2021 |
| Monitoring natural SARS-CoV-2 infection in lions (Panthera leo) at the barcelona zoo: viral dynamics and host responses H Fernández-Bellon, J Rodon, L Fernández-Bastit, V Almagro, ... Viruses 13 (9), 1683, 2021 | 59 | 2021 |
| Identification of plitidepsin as potent inhibitor of SARS-CoV-2-induced cytopathic effect after a drug repurposing screen J Rodon, J Muñoz-Basagoiti, D Perez-Zsolt, M Noguera-Julian, ... Frontiers in pharmacology 12, 278, 2021 | 58* | 2021 |
| Pigs are not susceptible to SARS‐CoV‐2 infection but are a model for viral immunogenicity studies J Vergara‐Alert, J Rodon, J Carrillo, N Te, N Izquierdo‐Useros, ... Transboundary and emerging diseases 68 (4), 1721-1725, 2021 | 57 | 2021 |
| SARS-CoV-2 interaction with Siglec-1 mediates trans-infection by dendritic cells D Perez-Zsolt, J Muñoz-Basagoiti, J Rodon, M Elosua-Bayes, ... Cellular & molecular immunology 18 (12), 2676-2678, 2021 | 49* | 2021 |
| Protection against reinfection with D614-or G614-SARS-CoV-2 isolates in golden Syrian hamster M Brustolin, J Rodon, ML Rodriguez de la Concepcion, C Ávila-Nieto, ... Emerging microbes & infections 10 (1), 797-809, 2021 | 47 | 2021 |
| Chronological brain lesions after SARS-CoV-2 infection in hACE2-transgenic mice E Vidal, C López-Figueroa, J Rodon, M Pérez, M Brustolin, G Cantero, ... Veterinary pathology 59 (4), 613-626, 2022 | 46 | 2022 |
| Cross-neutralization activity against SARS-CoV-2 is present in currently available intravenous immunoglobulins JM Díez, C Romero, J Vergara-Alert, M Belló-Perez, J Rodon, ... Immunotherapy 12 (17), 1247-1255, 2020 | 40 | 2020 |
| Preclinical and randomized phase I studies of plitidepsin in adults hospitalized with COVID-19 JF Varona, P Landete, JA Lopez-Martin, V Estrada, R Paredes, ... Life Science Alliance 5 (4), 2022 | 37* | 2022 |
| Blocking transmission of Middle East respiratory syndrome coronavirus (MERS-CoV) in llamas by vaccination with a recombinant spike protein J Rodon, NMA Okba, N Te, B van Dieren, BJ Bosch, A Bensaid, J Segalés, ... Emerging microbes & infections 8 (1), 1593-1603, 2019 | 33 | 2019 |
| Clinical course impacts early kinetics and long-term magnitude and amplitude of SARS-CoV-2 neutralizing antibodies beyond one year after infection E Pradenas, B Trinité, V Urrea, S Marfil, F Tarrés-Freixas, R Ortiz, ... Cell Reports Medicine, 100523, 2022 | 28* | 2022 |
| Previous SARS-CoV-2 infection increases B. 1.1. 7 cross-neutralization by vaccinated individuals B Trinité, E Pradenas, S Marfil, C Rovirosa, V Urrea, F Tarrés-Freixas, ... Viruses 13 (6), 1135, 2021 | 22 | 2021 |
| First Detection of SARS-CoV-2 Delta (B. 1.617. 2) Variant of Concern in a Dog with Clinical Signs in Spain L Fernández-Bastit, J Rodon, E Pradenas, S Marfil, B Trinité, M Parera, ... Viruses 13 (12), 2526, 2021 | 21 | 2021 |
| Unraveling the antiviral activity of plitidepsin against SARS-CoV-2 by subcellular and morphological analysis M Sachse, R Tenorio, IF de Castro, J Muñoz-Basagoiti, D Perez-Zsolt, ... Antiviral Research 200, 105270, 2022 | 18 | 2022 |
| Rapid SARS-CoV-2 Inactivation in a Simulated Hospital Room Using a Mobile and Autonomous Robot Emitting Ultraviolet-C Light C Lorca-Oró, J Vila, P Pleguezuelos, J Vergara-Alert, J Rodon, N Majó, ... The Journal of infectious diseases 225 (4), 587-592, 2022 | 17 | 2022 |
| Type I and III IFNs produced by the nasal epithelia and dimmed inflammation are features of alpacas resolving MERS-CoV infection N Te, J Rodon, M Ballester, M Pérez, L Pailler-García, J Segalés, ... PLoS pathogens 17 (5), e1009229, 2021 | 16 | 2021 |
| Preclinical evaluation of a COVID-19 vaccine candidate based on a recombinant RBD fusion heterodimer of SARS-CoV-2 A Barreiro, A Prenafeta, G Bech-Sabat, M Roca, EP Mur, R March, ... Iscience, 2023 | 13* | 2023 |
| Experimental and field investigations of exposure, replication and transmission of SARS-CoV-2 in pigs in the Netherlands RS Sikkema, T Tobias, N Oreshkova, E de Bruin, N Okba, F Chandler, ... Emerging microbes & infections 11 (1), 91-94, 2022 | 13 | 2022 |
Júlia Vergara-AlertStaff Scientist, IRTA-CReSA, BarcelonaVerified email at irta.cat
